Pakistan Introduces Mandatory E-Reporting For Adverse Drug Reactions

Companies submitting individual case safety reports in Pakistan will soon have to use a new e-Reporting system that is expected to simplify and streamline the submissions process.

Notebook Computer With National Flag Of Pakistan
Pakistan's new e-reporting system is designed to streamline the submission of adverse reactions (Shutterstock)

As of 8 November, all individual case safety reports (ICSRs) that are filed in Pakistan will have to be submitted via the regulator’s new e-Reporting System.

More from Pink Sheet

Peter Marks Resigns From US FDA, Warns Kennedy Does Not Want Truth On Vaccines

 

In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."

‘Pipeline In A Pill’ Or Pipe Dream? US FDA’s April Goal Dates Test Expansion Strategies

 

Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.

Newest HHS Staff Cuts Could Stymie CMS Health Plan Oversight

 
• By 

A former CMS manager worries casework and other necessary functions could suffer as a result of the 300 staff cuts at the agency that are part of a massive HHS restructuring.

Oncology Center Of Excellence Deputy Directors Kluetz, Theoret Join US FDA Exodus

 

The April departures of Paul Kluetz and Marc Theoret follow resignations by other senior agency scientific staff and come on top of HHS’ plans to lay off 3,500 FDA employees.

More from Drug Safety

CAR-T Warning Refinements Coming Soon From US FDA

 

The US FDA is expected to refine warnings recently added to CAR-T cell therapies about the risk of secondary malignancies after reassuring new data, which is a positive sign for the future of the therapies in autoimmune disorders.

US FDA Never Fully Enforced The Clozapine REMS. Now’s It’s Not Needed

 
• By 

The Risk Evaluation and Mitigation Strategy hindered access and burdened the health care system even though it was never fully implemented or enforced. The FDA still recommends prescribers monitor patients’ absolute neutrophil count to prevent severe neutropenia.

EU Product Liability Directive Could Spell Trouble For Non-EU Pharma Firms

 

The EU’s new Product Liability Directive will make it easier for European consumers to seek compensation relating to defective products even if manufacturers are based outside the bloc. Legal experts caution that this could have substantial implications for pharmaceutical companies.